Capmatinib

From WikiMD.org
Jump to navigation Jump to search

Capmatinib

Capmatinib (pronounced kap-ma-TIN-ib) is a kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC) that is locally advanced or metastatic. It is specifically used for patients with NSCLC whose tumors have a mutation in the MET gene, also known as MET exon 14 skipping.

Etymology

The name "Capmatinib" is derived from the chemical name of the drug, which is 5-[(1R)-1-(2,3-Dihydro-1H-inden-1-yl)ethyl]-8-(1-methyl-1H-pyrazol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one. The "Cap" comes from the first three letters of the chemical name, the "matin" is derived from the term "matinée", which refers to a morning performance, and the "ib" is a common suffix used in the names of kinase inhibitors.

Usage

Capmatinib is administered orally in the form of a tablet. The recommended dosage is 400 mg twice daily, taken approximately 12 hours apart. The drug should be taken on an empty stomach, at least 1 hour before or 2 hours after a meal.

Side Effects

Common side effects of Capmatinib include nausea, vomiting, fatigue, and shortness of breath. Serious side effects can include pneumonitis, hepatotoxicity, and renal toxicity.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski